MBX Biosciences (MBX) Capital Expenditures (2023 - 2026)
MBX Biosciences (MBX) reported Capital Expenditures of $437000.0 for Q1 2026, down 12.95% on a YoY basis from $502000.0 in Q1 2025, and up 139.37% sequentially from -$1.1 million in Q4 2025.
MBX Biosciences (MBX) Capital Expenditures (2023 - 2026) Analysis & Trends
MBX Biosciences (MBX) has 4 years of Capital Expenditures data on file, last reported at $437000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 12.95% year-over-year to $437000.0; the trailing twelve-month figure through Mar 2026 stood at -$39000.0 (down 103.54% YoY), and the FY2025 full-year result was $26000.0, down 97.03% from the prior year.
- Capital Expenditures advanced to $437000.0 in Q1 2026, from -$1.1 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $712000.0 in Q3 2024 to a low of -$1.1 million in Q4 2025.
- A 4-year average of $146600.0 and a median of $254000.0 in 2024 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 215.76% in 2025, while the deepest fall reached 1306.52% in 2025.
- Tracing MBX's Capital Expenditures over 4 years: stood at $129000.0 in 2023, then dropped by 28.68% to $92000.0 in 2024, then sank by 1306.52% to -$1.1 million in 2025, then surged by 139.37% to $437000.0 in 2026.
- Business Quant data shows MBX's Capital Expenditures at $437000.0 in Q1 2026, -$1.1 million in Q4 2025, and $399000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | MBX Biosciences | 2.96 Bn | 2.96 Bn | - | 437,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 437,000.00 |
| Mar 31, 2026 | 437,000.00 |
| Dec 31, 2025 | -1.11 Mn |
| Dec 31, 2025 | -1.11 Mn |
| Sep 30, 2025 | 399,000.00 |
| Sep 30, 2025 | 399,000.00 |
| Jun 30, 2025 | 235,000.00 |
| Jun 30, 2025 | 235,000.00 |
| Mar 31, 2025 | 502,000.00 |
| Mar 31, 2025 | 502,000.00 |
| Dec 31, 2024 | 92,000.00 |
| Dec 31, 2024 | 92,000.00 |
| Sep 30, 2024 | 712,000.00 |
| Sep 30, 2024 | 712,000.00 |
| Jun 30, 2024 | -203,000.00 |
| Jun 30, 2024 | -203,000.00 |
| Mar 31, 2024 | 273,000.00 |
| Mar 31, 2024 | 273,000.00 |
| Dec 31, 2023 | 129,000.00 |
| Dec 31, 2023 | 129,000.00 |